Loading...
OTCM
BCLI
Market cap6mUSD
Dec 05, Last price  
0.60USD
1D
-1.48%
1Q
-15.49%
Jan 2017
-98.43%
IPO
-99.48%
Name

Brainstorm Cell Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:BCLI chart
P/E
0.57
P/S
7.80
EPS
1.05
Div Yield, %
—
Shrs. gr., 5y
-24.68%
Rev. gr., 5y
%
Revenues
849k
00000000000000-366,0000000849,000
Net income
12m
P
-18,839,795-3,924,485-6,244,000-3,472,000-1,781,000-2,419,000-3,918,000-3,430,000-4,899,000-9,246,000-8,488,000-4,982,000-4,952,000-13,833,000-23,505,000-31,938,000-24,375,000-23,732,000-17,192,00011,623,000
CFO
-9m
L-55.55%
-677,836-854,643-1,774,000-1,734,000-744,000-2,069,000-2,223,000-2,916,000-4,054,000-4,487,000-7,408,000-5,858,000-2,364,000-12,388,000-11,247,000-35,193,000-26,265,000-19,320,000-20,458,000-9,093,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
URL
https://brainstorm-cell.com/
IPO date
May 28, 2003
Employees
44
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT